Ischemic Stroke News and Research RSS Feed - Ischemic Stroke News and Research

Male stroke patients who live alone are at greater risk of premature death

Male stroke patients who live alone are at greater risk of premature death

Men who live alone have a considerably greater long-term risk of dying prematurely than other patients. This is shown in a doctoral thesis that followed 1,090 stroke cases in western Sweden. [More]
Daiichi Sankyo receives FDA approval for SAVAYSA (edoxaban) Tablets

Daiichi Sankyo receives FDA approval for SAVAYSA (edoxaban) Tablets

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration has approved SAVAYSA (edoxaban) Tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF). [More]
Study: Placental cells may possibly treat damaged nerves

Study: Placental cells may possibly treat damaged nerves

New findings suggest that placental cells may potentially treat damaged nerves possibly leading the way to new treatment for stroke patients. [More]
Novastem uses Stemedica's stem cell products to treat patient in ischemic stroke study

Novastem uses Stemedica's stem cell products to treat patient in ischemic stroke study

Novastem, a leader in regenerative medicine, announces the treatment of its first patient in its study for ischemic stroke at Clinica Santa Clarita. [More]
Treatment for stroke: Intra-arterial treatment more effective than standard medical care for clot removal

Treatment for stroke: Intra-arterial treatment more effective than standard medical care for clot removal

Study results released today in The New England Journal of Medicine gave the world of stroke care more evidence that physicians are winning the battle against this debilitating disease, which affects as many as one in six people. [More]
Intra-arterial stroke treatment more effective than medical management with tPA, study finds

Intra-arterial stroke treatment more effective than medical management with tPA, study finds

Penumbra, Inc., the market leader in intra-arterial stroke treatment, announced that an independent study published online today in the New England Journal of Medicine found that intra-arterial stroke treatment, including the company's clot extraction technology, was shown to be significantly more effective than medical management with tissue plasminogen activator (tPA), which is the current standard of care. [More]
Daiichi Sankyo releases new formulation of LIXIANA 60 mg Tablets

Daiichi Sankyo releases new formulation of LIXIANA 60 mg Tablets

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched a new formulation of LIXIANA 60 mg Tablets (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban, approval to market: September 26, 2014; NHI drug price listing: November 25, 2014) in Japan for the recently approved indications: the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and the treatment and recurrence prevention of venous thromboembolism (VTE) [deep vein thrombosis (DVT) and pulmonary thromboembolism (PE)]. [More]
Researchers uncover easily detectable, 'pre-malignant' state in the blood

Researchers uncover easily detectable, 'pre-malignant' state in the blood

Researchers from the Broad Institute of MIT and Harvard, Harvard Medical School, and Harvard-affiliated hospitals have uncovered an easily detectable, "pre-malignant" state in the blood that significantly increases the likelihood that an individual will go on to develop blood cancers such as leukemia, lymphoma, or myelodysplastic syndrome. [More]
Hospital bed positioning can affect outcomes of stroke patients

Hospital bed positioning can affect outcomes of stroke patients

During the first 24 hours after a stroke, attention to detail --such as hospital bed positioning -- is critical to patient outcomes. [More]
FDA recommens approval of Daiichi Sankyo's once-daily SAVAYSA for patients with NVAF

FDA recommens approval of Daiichi Sankyo's once-daily SAVAYSA for patients with NVAF

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee voted 9 to 1 to recommend approval of once-daily SAVAYSA (edoxaban) 60 mg dosing regimen for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF). [More]
UCLA earns Get With The Guidelines-Stroke Gold-Plus Quality Achievement Award

UCLA earns Get With The Guidelines-Stroke Gold-Plus Quality Achievement Award

he UCLA Comprehensive Stroke Center at Ronald Reagan UCLA Medical Center has received the Get With The Guidelines-Stroke Gold-Plus Quality Achievement Award for implementing specific quality improvement measures outlined by the American Heart Association/American Stroke Association for the treatment of stroke patients. [More]
Monash University research explores long-term costs for two main causes of stroke

Monash University research explores long-term costs for two main causes of stroke

New data shows that healthcare and personal costs to support survivors of stroke remains high 10 years on. [More]
New research reveals innovative way to classify severity of stroke

New research reveals innovative way to classify severity of stroke

New research conducted at the Florida State University-based National High Magnetic Field Laboratory has revealed a new, innovative way to classify the severity of a stroke, aid in diagnosis and evaluate potential treatments. [More]

Clot-buster shows promise in treating less severe forms of traumatic brain injury

The only drug currently approved for treatment of stroke's crippling effects shows promise, when administered as a nasal spray, to help heal similar damage in less severe forms of traumatic brain injury. [More]
Mfn2 protein: A future therapeutic target for neuronal death reduction in ischemic stroke

Mfn2 protein: A future therapeutic target for neuronal death reduction in ischemic stroke

A new study published in the prestigious publication The EMBO Journal shows that the mitochondrial protein Mfn2 may be a future therapeutic target for neuronal death reduction in the late phases of an ischemic stroke. [More]
Covidien begins enrollment in two clinical trials for advanced neurovascular solutions

Covidien begins enrollment in two clinical trials for advanced neurovascular solutions

Covidien plc announced today the start of enrollment in two clinical trials designed to further underscore the safety and effectiveness of the company’s advanced neurovascular solutions. [More]
Codman reaches exclusive distribution agreement with Pulsar Vascular to market PulseRider

Codman reaches exclusive distribution agreement with Pulsar Vascular to market PulseRider

Codman Neuro, part of DePuy Synthes Companies of Johnson & Johnson, today announced it has reached an exclusive distribution agreement with Pulsar Vascular to market and promote that company's PulseRider® in Europe, the Middle East and Africa. [More]

Codman Neuro signs distribution agreement with Pulsar Vascular for PulseRider device

Codman Neuro, part of DePuy Synthes Companies of Johnson & Johnson, today announced it has reached an exclusive distribution agreement with Pulsar Vascular to market and promote that company’s PulseRider in Europe, the Middle East and Africa. [More]

Codman Neuro Receives Approval for REVIVE SE Thrombectomy Device in China, South Korea and Taiwan

Codman Neuro, part of DePuy Synthes Companies of Johnson & Johnson, announced regulatory approval from the China Food and Drug Administration, South Korea’s Ministry of Food and Drug Safety, and the Taiwan Food and Drug Administration for the company’s REVIVE SE Thrombectomy Device, a next-generation self-expanding clot removal device intended to restore blood flow in patients with acute ischemic stroke secondary to intracranial occlusive vessel disease. [More]
Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen Research & Development, LLC and its development partner, Bayer HealthCare, announced today the expansion of the EXPLORER global cardiovascular research program for XARELTO (rivaroxaban) to include additional high-risk patient populations. [More]